Department of Medicine (Oncology) and NYU Cancer Institute, New York University School of Medicine, New York, NY 10016, USA.
Anticancer Res. 2012 Apr;32(4):1327-31.
Tamoxifen or raloxifen for 5 years reduces the risk of developing invasive breast cancer by 40%. To address safety concerns and seek enhanced efficacy, studies of new chemopreventive agents using mammographic density as a surrogate end point are attractive.
Postmenopausal women with risk factors for developing breast cancer were given letrozole 2.5 mg daily for one year, and mammographic density was the biomarker of breast cancer risk modification. It was assessed (blinded to the reader) at baseline, 6, and 12 months in 16 evaluable women among 20 enrolled.
Eight patients exhibited decreased mammographic density at six months, and eleven at 12 months. Toxicities included joint aches not precluding continued treatment.
This pilot study supports the use of letrozole for reducing breast cancer risk. In addition, it encourages prospective studies of serial changes in mammographic density as a biomarker of risk modification within a selected high-risk population.
他莫昔芬或雷洛昔芬治疗 5 年可降低 40%的浸润性乳腺癌发病风险。为解决安全性问题并寻求更好的疗效，以乳腺密度为替代终点的新化学预防药物的研究具有吸引力。
有发生乳腺癌风险的绝经后妇女每日给予来曲唑 2.5mg，持续 1 年，乳腺密度是乳腺癌风险改变的生物标志物。在 20 名入组患者中，有 16 名可评估患者的乳腺密度在基线、6 个月和 12 个月时进行了评估（盲法）。
8 例患者在 6 个月时乳腺密度降低，11 例在 12 个月时降低。关节疼痛等毒性反应并不妨碍继续治疗。
这项初步研究支持来曲唑用于降低乳腺癌风险。此外，它鼓励对特定高危人群中乳腺密度的连续变化作为风险改变的生物标志物进行前瞻性研究。
